March 11, 2026 · The American journal of medicine · DOI: 10.1016/j.amjmed.2026.02.016

Glucagon-Like Peptide-1 Receptor Agonist and Lupus Nephritis in Systemic Lupus Erythematosus with Type 2 Diabetes

Listen to this summary

The authors aimed to investigate the association between glucagon-like peptide-1 receptor agonist (GLP-1 RA) exposure and renal and inflammatory outcomes in patients with systemic lupus erythematosus (SLE) and type 2 diabetes mellitus. Their findings suggest that GLP-1 RA exposure is linked to a reduced risk of lupus nephritis and SLE flares over one year, indicating potential therapeutic benefits for this patient population.

Muhammad Hanif, Jai S Nagarajan, Ryan Murphy, Shiva P Sah, Shuang Ye, Andras Perl, Cynthia C Taub

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play